Status: Recruiting
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.
Participants needed: 168
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: OncoNano Medicine, Inc.Updated: Dec 24, 2025Locations: 16
Eligibility criteria
Ability to understand and willingness to sign written informed consent before pe... [+6]
Other malignancy active within the previous 2 years except for basal or squamous... [+12]